Home > Insider Trading > Filing (0001661181-21-000025)

Filing Details

Accession Number:: 0001661181-21-000025
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-18 20:34:13
Reporting Period:: 2021-02-16

Accepted Time:: 2021-02-18 20:34:13
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1661181	Organogenesis Holdings Inc.	ORGO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1757373	S. Gary Gillheeney	C/O Organogenesis Holdings Inc. 85 Dan Road Canton MA 02021	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Acquisiton	2021-02-16	51,626	$0.00	245,845	No	4	A	Direct
Class A Common Stock	Disposition	2021-02-17	78,201	$13.30	167,644	No	4	S	Direct
Class A Common Stock	Disposition	2021-02-17	11,174	$13.82	156,470	No	4	S	Direct
Class A Common Stock	Disposition	2021-02-18	16,663	$12.85	139,807	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Stock Option (Right to Buy)	Acquisiton	2021-02-16	395,289	$0.00	395,289	$13.68

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
395,289		2031-02-16	No	4	A	Direct

Footnotes

Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.76 to $13.75, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.76 to $13.90, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.62 to $13.265, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
The option becomes exercisable in equal annual installments over four years beginning February 16, 2021.